Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9 at 4:40 p.m. ET. The event will be available for live streaming on Kymera's website, with a replay accessible for one month afterward. Kymera is a biopharmaceutical company focused on targeted protein degradation, aiming to develop innovative therapies for chronic diseases. Their proprietary platform enables the creation of small molecule degraders to tackle disease-causing proteins.

WATERTOWN, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in a virtual fireside chat at the Goldman Sachs 42^nd Annual Global Healthcare Conference on Wednesday, June 9 at 4:40 p.m. ET.

A live webcast of the event will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available for one month following the event.

About Kymera Therapeutics
Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera’s goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable.

Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston’s “Best Places to Work.” For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.

Investor Contact:
Paul Cox
VP, Investor Relations and Communications
pcox@kymeratx.com
917-754-0207

Media Contact:
Lissette L. Steele
Verge Scientific Communications for Kymera Therapeutics
lsteele@vergescientific.com
202-930-4762

FAQ

When is Kymera Therapeutics participating in the Goldman Sachs 42nd Annual Global Healthcare Conference?

Kymera Therapeutics will participate on June 9 at 4:40 p.m. ET.

How can I watch the Kymera Therapeutics fireside chat?

The fireside chat can be streamed live on Kymera's website under the 'Events and Presentations' section.

What is the focus of Kymera Therapeutics' research?

Kymera specializes in targeted protein degradation to develop therapies for challenging diseases.

What are some of Kymera's initial programs?

Kymera's initial programs include IRAK4, IRAKIMiD, and STAT3, focusing on immune-inflammatory diseases and cancers.

Where is Kymera Therapeutics headquartered?

Kymera Therapeutics is headquartered in Watertown, Massachusetts.